Clinical trials

The goal of the CFF Registry is to develop and maintain a database of CF patients that collects and stores de-identified patient medical information and other related information. This information is used to create CF care guidelines, assist care teams providing care to individuals with CF and guide quality improvement initiatives at care centers. Researchers also use the Patient Registry to study CF treatments and outcomes and to design CF clinical trials.

The purpose of this research is to compare the effects, good or bad, of the investigational drug TTI-101 versus placebo in people with idiopathic pulmonary fibrosis (IPF). This research will also assess the effect of TTI-101 on lung function.

The purpose of this research is to see if LP-300 affects the survival of subjects who have never smoked but developed advanced lung cancer despite taking one or more targeted treatments against the lung cancer.

The first stage of the trial will examine the safety of LP-300 used in combination with standard cancer treatments (carboplatin and pemetrexed) in the first six subjects, in which all subjects will receive LP-300 with carboplatin and pemetrexed. In the second stage of the study, subjects will be assigned to one of the treatment arms by chance (like a coin-flip), with about 2 out of 3 subjects receiving the investigational drug, LP-300, along with standard cancer treatment, and 1 out of 3 subjects receiving standard cancer treatment alone. The major purpose of this stage of the trial is to determine if LP-300 in combination with standard treatment has a different effect on the cancer in subjects who have never smoked than the standard treatment alone in subjects who have never smoked.

This research is being performed because improvements are needed in the treatment management of subjects with cancer.

Phase I: To determine the safety, tolerability and recommended phase II dose (RP2D) of the combination of ADI-PEG 20, gemcitabine, and docetaxel when given to patients with small cell and non-small cell lung cancers that have progressed on frontline therapy


Phase II: To determine objective response rate (ORR) in two cohorts: (1) patients with small cell lung cancers that have progressed on frontline therapy who are treated with ADI-PEG 20 in combination with gemcitabine and docetaxel and (2) patients with non-small cell lung cancers that have progressed on frontline therapy who are treated with ADI-PEG 20 in combination with gemcitabine and docetaxel.

To evaluate the effect of seralutinib compared to placebo on exercise capacity after 24 weeks of treatment when added to background PAH disease-specific medication